Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Earlier this year, idecabtagene vicleucel (Abecma), a chimeric antigen receptor (CAR)-T cell therapy targeting B cell maturation antigen (BCMA) was approved by the FDA for the treatment of multiple myeloma, becoming the first CAR-T cell therapy for a target other than CD19 to receive approval. There are currently five cell therapies approved by the FDA, all of which are CAR-T cell therapies. This analysis gives an updated view of the cancer cell therapy landscape, including the global R&D pipeline of agents, the status of clinical trials, and real-world data evidencing their current use in clinical practice.
